# Bio-Rad Laboratories

> Bio-Rad Laboratories is a VC fund backing Health Care and Biotechnology. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Hercules, United States
- Total investments: 7
- Last investment: Feb 2026
- Lead investor: 57%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/bio-rad?trk=top_nav_home
- Website: http://www.bio-rad.com/

Bio-Rad Laboratories is a VC fund in Hercules focused on Health Care and Biotechnology. Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of innovative tools and services to the life science research and clinical diagnostics markets. Founded in 1952, Bio-Rad has a global team of more than 6,500 employees and serves more than 85,000 research andindustry customers worldwide through its global network of operations. Throughout its existence, Bio-Rad has built strong customer relationships that advance scientific research and development efforts and support the introduction of new technology used in the growing fields of genomics, proteomics, drug discovery, food safety, medical diagnostics, and more.

## Contacts

5 contacts available for Bio-Rad Laboratories. Shizune tracks 8 team members at Bio-Rad Laboratories. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/bio-rad-laboratories?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 43% |
| Biotechnology | 3 | 43% |
| Genetics | 2 | 29% |
| Health Diagnostics | 2 | 29% |
| Medical | 1 | 14% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 29% |
| Post-IPO Equity | 2 | 29% |
| Series C | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 29% |
| Canada | 1 | 14% |
| Norway | 1 | 14% |
| United Kingdom | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alice Schwartz | Co-Founder | 0 | — |
| James Stark | Vice President, Corporate Controller | 0 | — |
| Kalyan Handique | VP, CDG Advanced Technology | 0 | — |
| Monica Niblack | Business Analyst Intern | 0 | — |
| Norman D. Schwartz | CEO | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| iMDx | iMDx is a molecular diagnostics company that develops and offers blood-based tests for oncology and transplant care. The company offers assays such as GraftAssureCore (a lab test for transplant rejection), GraftAssureIQ (a research-use kit), and DetermaIO for immunotherapy guidance. The company holds CLIA and state lab certifications. | $26M | Post-IPO Equity | Feb 11, 2026 |  |
| Genetic Analysis | Genetic Analysis AS (GA) has the goal of being a leader within the field of molecular diagnostics of diseases related to gut imbalances. By utilizing the DNA-based GA-map™ array technology, profiles of a patient’s gut microbiota is quickly generated and can be related to various health conditions. Genetic Analysis has developed a DNA-basedtechnology platform that allows for simultaneous analysis of a large number of similarities (but not identical) gene fragments in one reaction. The company’s focus is to utilize this technology platform to identify variations in the hundreds of different bacteria that exist in the gut (large and small intestine). The GA - map makes it possible, for the first time, to offer a diagnostic solution – including early detection - for many diseases that are affected by imbalances in the gut microbiota. Genetic Analysis will offer kits and services for a wide range of applications. | $1.2M | Post-IPO Equity | May 05, 2025 |  |
| Afynia Laboratories | Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis. | $5M | Seed | Feb 25, 2025 |  |
| iMDx | iMDx is a molecular diagnostics company that develops and offers blood-based tests for oncology and transplant care. The company offers assays such as GraftAssureCore (a lab test for transplant rejection), GraftAssureIQ (a research-use kit), and DetermaIO for immunotherapy guidance. The company holds CLIA and state lab certifications. | $29.1M | Post-IPO Equity | Feb 10, 2025 |  |
| Geneoscopy | Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications. | $105M | Series C | Jan 08, 2025 |  |
| iMDx | iMDx is a molecular diagnostics company that develops and offers blood-based tests for oncology and transplant care. The company offers assays such as GraftAssureCore (a lab test for transplant rejection), GraftAssureIQ (a research-use kit), and DetermaIO for immunotherapy guidance. The company holds CLIA and state lab certifications. | $10.2M | Post-IPO Equity | Oct 02, 2024 |  |
| Oxford Impedance Diagnostics Ltd. | Oxford Impedance Diagnostics Ltd. researches, designs and will market diagnostic tests for the measurement of clinical bio markers that reduce healthcare costs and improve patient outcomes. | $2.6M | Seed | Jul 25, 2016 |  |

7 of 7 investments shown.

## Co-investors
- [Arvo Invest](https://shizune.co/investors/profile/arvo-invest) — VC Fund, 1 deal together
- [Capital Angel Network](https://shizune.co/investors/profile/capital-angel-network) — VC Fund, 1 deal together
- [Gaingels](https://shizune.co/investors/profile/gaing) — VC Fund, 1 deal together
- Granger Management LLC — VC Fund, 1 deal together
- [Impact America Fund](https://shizune.co/investors/profile/impact-america-fund) — VC Fund, 1 deal together
- Karlander Eiendom — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Bio-Rad Laboratories invest in?

Bio-Rad Laboratories invests primarily in Health Care, Biotechnology and Genetics startups, most often at Seed and Post-IPO Equity stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Bio-Rad Laboratories?

Public channels for Bio-Rad Laboratories include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Bio-Rad Laboratories?

The team at Bio-Rad Laboratories includes Alice Schwartz (Co-Founder), James Stark (Vice President, Corporate Controller) and Kalyan Handique (VP, CDG Advanced Technology), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co